THE magnlitude of the literature dealing with deep thrombophlebitis of the lower extremities and its complications reflects not onily the interest that this disorder commands among physicians but also the extensive controversy that it has generated. Controversy surrounds even such fundamental problems as the pathogenesis of venous thromboembolism, the natural course of the process, and the adequacy of available diagnostic criteria. When viewed against this background of debate over basic issues, the differences of opinion regarding the effects of various forms of therapy in acute deep venous occlusion are readily understood.
Venous ligation and anticoagulant therapy alone or in combination have attracted strong advocates. 2'4, 7. 8, 20-22 This debate over therapy is complicated by the variations in the specific manner in which therapy is applied. 4' 17, 20-27 Furthermore the results can be interpreted only after consideration of the criteria used for selection of patients, the specific measures of improvement, and the therapeutic objectives. Since methodologic details obviously influenee the results and since identical methods rarely have beeni used in evaluation of therapeutic agents in thrombophlebitis, the obvious corollary has been a wide divergence ill results. 2 Recentlv, a new aspect has been added to From "fibrinolytic or thrombolytie agents," sinee they can induce the lysis of fibrin, the protein which provides the framework of intravascular thrombi. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Materials labeled as "fibrinolytic agents" Xvary widely in origin, composition, and mechaiiism of action.40 42 All of them, however, act by influencing or supplementing the normal components of the intrinsic fibrinolytic mechanism present in the blood ( fig. 1 43, 44 These studies indicated that this preparation (a highly purified profibrinolysin activated with streptokiiiase and thenl further purified) was acceptable for use in humani subjects although it was niot devoid of side effects, particularly pyrogenicity. Fur Dia.grarmknatic representation of the normal fibri-uolytic mechanism and the influence of various "fibrinolytic agents`upon it.
and venous thrombotic disorders. Carefully controlled studies were necessarv, however.
to confirm these preliminary impressions of the therapeutic value of fibrinolysiln. The first entity choseni for controlled hiivestigation was acute deep venous thrombosis of the lower extremities. This particular thrombotic disorder was selected for several reasoins: (1) it is encountered frequently at the institutions cooperating in this study; (2) any teiiperature elevatioln occasioned by fibrinolysin would be unlikely to have deleterious effects upon these patieints; (3) the mortality associated with thrombophlebitis is low and would grant an opportunity for follow-up in most instances; (4) some objective criteria exist for determining the therapeutic effect of a given regimen; and (5) the available methods of therapy are not ideal.
In regard to this last point, the ideal therapeutic regimen in patients with acute dcl) venous occlusioln would achieve 4 major goals: the rapid relief of aeute signs and symptoms with early returni of the patient to normal activity; the prevenition of pulmonary embolism; the prevention of permanent residuals such as the postphlebitic syndrome; anid the prevention of phlebitic reeurrence.
The study reported here is ain attempt to ascertain whether a combinied fibrinolytic-anticoagulant therapy attains these 4 objectives more adequately than anticoagulant therapy alone. The data presented are derived from the first 62 patientts studied.
Methods of Study Fibrinolysin
The fibrinolysin preparation used in this study' is derived from the euglobulin fraction of the human plasma proteins as pro-fibrinolysin and is activated by small amounts of highly purified streptokinase. Procedures are then employed to obtain an end-product free of detectable streptokinase activity and the material is lyophilized. The precise methods used in isolation, purification, and activation of the material are not available for publication. Studies in our laboratory with the fibrin plate methods of Astrup and Mullertz47 and Lassen48 have indicated that the material cointains both "activator" and "enzyme" activity. The preparation is standardized by the nmanufacturer by both fibrinolytic and nonfibrinolytic technics. In our laboratory, the potency of each lot received is compared with a house standard by a fibrinolytic assay method.31 The lyophilized material is stable for insanv weeks at 5 C. It is dissolved in normal saline or 5 per cent dextrose solution just prior to use.
Criteria for Inclusion of Patients
The patients in this series include all individuals seen by the authors during a 2-year period in whom unequivocal signs of acute deep venous occlusion of the legs had been present for 10 days or less. All patients with questionable or minimal evidence of occlusion, complicating cellulitis, or mild exacerbation of chronic venous disease were excluded.
The double-blind technic of study was not feasible in this series because of (1) the pyrogenicity of the fibrinolysin preparation and (2) the desire to obtain serial blood samiiples and other data (electrocardiogram, temperature response, etc.) in those receiving fibrinolytic therapy. Therefore, an alternating teehnic of controlled study was employed. Each patient was assigned a number in sequence. All even-nunmbered patients served as controls while all odd-numbered patients received fibrinolytic therapy. No deviation from this sequential assignment was permiiitted, with 1 exception; namely, in patients who had received anticoagulant therapy for more than 24 hours prior to their referral. The following arbitrary procedure was followed wheni such patients were encountered:
(1) if the protocol for the study had not been followed or adequate records were not available regarding initial and subsequent status of the leg, the patient was eliminated fromi the series; (2) if the first criterion was satisfied, the patient was assigned a sequential number. If this was an even (control) numiiber, the patient was continued in tonis prior to institution of control or fibrinolytic therapy and (2) uncontrollable deviations from the protocol regarding duration of anticoagulant therapy, tinme of ambulation, or time of discharge. In addition, the inclusioni of fibrinolysin-treated patients who received anticoagulant drugs for more than 24 hours before fibrinolysin was administered might penalize this group, since the duration of signs and symptoms was dated from the start of anticoagulant therapy.
ITn order to evaluate these factors results have been analyzed in several ways: 1. The "gross" results in both groups are reported;
i.e., the actual duration of anticoagulant therapy, duration before ambulation was permissible, etc. In addition, in order to eliminate the distortion of gross results due to uncontrollable factors (other disorders present. physician preference, missed orders, etc.), 'arbitrary" results for duration of anticoagulation, bed rest, and hospital stay are also presented. These "arbitrary" results were derived as follows: the day on which all signs Circulation, Volime XXI, March 1960 PIBRINOLYSIN THEIRAPYV or symptoms of active phlebitis (pain, tenderniess, turgidity, heat of the extremity, anid systemic tenmperature elevation) had subsided was takeii as the starting point. In keeping with the protocol "arbitrary " ambulation represents this figure plus 2 days; "arbitrary" discontinuance of anticoagulant drugs, this figure plus 4 days; "arbitrary" discharge, this figure plus 6 days. Thus, if a patient's phlebitis was inactive on day 3 after start of anticoagulant drugs, he "arbitrarily" would be ambulated on day 5, have anticoagulants discontinued on day 7, and be discharged on day 9.
2. Patients from the 2 groups who met the following criteria were selected for separate analysis: all control patients in whom anticoagulant therapy was begun 3 days or less after onset of symptoms (26 patienits) ; all patients treated with fibrinolysin within 5 days after onset of symptoms and within 24 hours after anticoagulant therapy was instituted (21 patients). Again, both "actual" and "arbitrary" values are reported for duration of anticoagulation, bed rest, and hospital stay.
3. In both the subgroups and total groups, "short-term" and "long-term" results are analyzed separately. The former category ineludes the response of the involved extremity, the incidence of embolization or recurrence of phlebitis during the first 2 weeks following institution of therapy (or until discharge if the patient was discharged before this time and not seen subsequently), and the status of the extremity at the time of hospital discharge. "liong-term" results include any recurrence of phlebitis or pulmonary emboli that appeared more than 2 weeks after start of anticoagulant therapy. With rare exceptions these represent results in individuals no longer receiving anticoagulant drugs.
We should emphasize that the time intervals reported here are dated from the start of anticoagulant therapy, not from the onset of symptoms, admission, or administration of fibrinolysin. Therefore, day zero is the day on which anticoagulant therapy (heparin) was started.
Total Group, Short-Term Results (Tables 3 and 4) Subsidence of Pain and Tenderness Pain and teniderness were considered to be absent whein the Homans' sign and the Lowenberg test51 were negative, and squeezing or vigorous palpation of the involved areas did not cause discomfort. These are rather stringent criteria, sinee patients often report they are pain-free while such maneuvers continue to elicit pain. In the control group, pain persisted longer after start of anticoagulant therapy than in the fibrinolysin group.
Edema
Edema was defined as absent when all p)itting edema had subsided.
Leg Size Normal
Calf measurements were made at 10-cm. intervals above the lower border of the internal malleolus. The thigh was measured at 10-cm. intervals above the tibial tubercle. The involved extremity was considered to have returned to normal size when no eircumference was more than 2.0 cm. greater than the uninvolved leg.52 In 3 control patients and 3 patients receiving fibrinolysin, leg size failed to return to normal during hospitalization. There was no significant difference in the remainder of the 2 groups in this time.
Bed Rest
Bed rest was longer in the control group than in the fibrinolysin group. Two patients in the control group who died while still at bed rest were excluded from analysis.
Duration of Anticoagulant Therapy
The duration of anticoagulant therapy was longer in the control group than in the fibrinolysin group. Two patients were excluded in whom anticoagulant drugs were continued indefinitely for reasons other than thrombophlebitis.
Duration of Hospital Stay
The duration of hospital stay after start of therapy for thrombophlebitis was also longer in the controls than in those treated with fibrinolysin.
Circulation, Volume XXI, Marcht 1960 showed evidenee of venous insufficiency at the time of discharge. In onie, this evidence consisted of a 2.5-em. discrepaniey in leg size that persisted during a 3-week period after a left iliofenioral occlusion. No edema on ambulation or other signs or symnptoms were present. The second patient was discharged with slight edema following a popliteal thrombosis. However, pretibial and pedal edema developed after moderate periods of ambulation. Ten fibrinolysin-treated patients had a previous history of venous disease. Three of these had well-documented, prior postphlebitic defects. Evidence of ehronic venous insufficiency at discharge was limited to these 3 patients. As far as could be ascertained, the degree of inisufficiency increased in 1 patient and had renmained unchanged in the other 2.
Recurrence of Phlebitis lIi the control group, 2 recurrences appeared within the 2 weeks after therapy was begun, on the twelfth ancd fifth days. Both patients were ambulatory at the time of recurrence, and one was still on anticoagulant therapy. tMultiple in 1 of these 4 patients.
ln the fibrinolysin-treated group, nio recurrenees appeared during this 2-week interval.
Deaths
One "'short-term" death was encountered in each group. As mentioned above, the death in the control group occurred suddenly on the eighth day of anticoagulant therapy, presumably due to a pulmonarv embolus. The fibrinolysin-treated patient had ehronic azotemia and died of progressive uremia 6 days after therapy. The right femoral thrombophlebitis had cleared completely within 3 days. Autopsy revealed a patent left femoral vein and no evidence of pulmonary embolization. Both kidneys were severely hydronephrotic and virtually replaced by masses of renal calculi.
Total Group, Long-Term Results
The long-term results (after the initial 2-week period) obviously are influenced by the extent of follow-up in the 2 groups. The median duration of follow-up in the 2 groups is the same, whereas the average duration is longer in the controls than in those treated with fibrinolvsin (table 5) .
Pulmnonary Embolization
Of the 24 control patienits followed more than 2 weeks, 4 (17 per cent) had one or more episodes of pulmonary embolizatioii ( Of the 24 control patients followed for more than 2 weeks, 6 recurrences appeared in 4 patients. One patient developed a recurrence at 17 days with unevenitful recovery. In another, recurrence appeared during the third month of follow-up and the patient succumbed to septiceiiia and pulmonary embolization. The third patient had a recurrence at 1 month and died 6 weeks later with pulmonary embolizatioii and congestive healrt failure. The fourth patient had reeurreniees at 1, 2, and 3 mnonths after discharge but for the subsequent 6 iimonths she had no further complaints other thani severe postphl]ebitic changes of the involved extremity.
In the 25 fibrinolysin patients followed ilore than 2 weeks, 3 recurrences were observed. Two "early" recurrences appeared in the 26 control patients versus none in the fibrinolysin group. Six "late" recurrences appeared in 4 of the 18 control patients followed for more than 2 weeks (22 per cent) versus 3 recurrences in 3 of the 16 fibrinolysin patients.
Deaths
One "short-termi" death occurred in each g,roup. Pulmonary embolisnm was the probable cause in the control patient and uremia in the fibrinolysin patient. Of the 3 "long-term " deaths in the control series, 2 were due to pulmonary embolism and embolization contributed to death in the third. The one "longterm" fibrinolysin death resulted from metastatic carcinioma of the pancreas.
Toxicity
As has been our experience in the past, the toxicity accompanying fibrinolysin infusion was limited primarily to temperature elevation. 43 44 Approximately half of the 42 infu-3MOSER, SULAVIK, HAJJA11 Since fibrinolysin is derived from plasma proteins, some concern regarding possible untoward effects in patients with allergic backgrounds is warranted. In the present series, onie patient with a history of bronchial asthma and another with rheumatoid arthritis received the miaterial without significant reaction. One subject with knowni penieillini sensitivity developed an urticarial rash at the site of inifusion. Our total experieniee now ineludes a number of patients with bronchial asthma, hay fever, and various "collagen" disorders. These patients do not have a higher ineidence of febrile or other reactions than other individuals, with perhaps one exception: of 5 patients with rheumatoid arthritis who received fibrinolysin, 3 had slight to moderate increase in joint signs and symptoms some 24 to 48 hours after infusion. At the present time, therefore, the use of plasmini does not appear to be contraindicated in patients with allergic or collagen-vascular dis orders, although observations in subjects with rheumatoid arthritis should be extended ini this regard.
Discussion
Theoretically, the combination of an effective thrombolytic drug with anticoagulant therapy should be more effective in the treatment of thrombophlebitis than anticoagulant Circulation, Volume XXI, March 1960 therapy alone. Acute dissolution of the offending thrombus would promptly relieve venous occlusion and hasten return of the extremity to normal. Fibrinolytic therapy also should reduce the incidence of pulmonary embolization by eliminating the embolic source, particularly sinee it should be most effective against the relatively fresh thrombotic zones which may be most likely to fragment. The postphlebitic syndrome, a manifestation of chronic deep venous obstruction, should be reduced in incidence and severity if thrombolysis can be achieved promptly.
The possible value of short-term thrombolytic-anticoagulant therapy in reducing the frequency of phlebitic recurrence is less clear. If recurrence is related to the speed or extent of thrombus removal following an episode of venous occlusion, the incidence of recurrenee should be lowered by addition of thrombolytic agents. If, on the other hand, recurrence is determined by a primary vascular abnormality or alteration in veuious blood flow, or by a hypercoagulable state that persists or returns following the phlebitic event,53' 54 total clot removal would not alter the tendency toward recurrence. In the latter cases, only prolonged anticoagulant therapy would provide protection against redevelopment of venous thrombosis and its complications.
Several factors other than potency of the drug itself are critical in determining the clinical response to fibrinolysin.30' 43 44 1. The diagnosis of thrombophlebitis (or other thrombotic disorders) must be established as firmly as possible. Fibrinolysin will not influence the course of cellulitis, muscle pain of traumatic or nonspecific origin, or edema due to congestive heart failure, etc. Therefore, patients were not included in this study if the diagnosis appeared equivocal or other explanations for the signs and symptoms were available.
2. An adequate dosage of fibrinolysin must be administered. This condition cannot be fulfilled with certainty at the present time in view of the controversy surrounding the in Circnlation, Volume XXI, March 196Q vivo behavior of fibrinolysin in the plasma and at the level of the clot itself.34 40 45 In the present study, an acceptable dose of flbrinolysin was considered to be one that produces detectable plasma fibrinolytic activity in 90 per cent or more of patients. Previous investigations had indicated that this point was reached when 75 000 to 100,000 fibrinolytic units were administered over a 2-to 4-hour period.3' Clinical observations also suggested that 1 such dose per 24 hours produced a clinical response in most phlebitic subjects and that repetition the second day often led to further improvement. A third dose rarely altered the course of patients who had not responded to the first 2 infusions.43' 44 Therefore, in the present study no patient in the fibrinolysin group received more than 2 doses of fibrinolysin. Whether the regimen used in this investigation is excessive or suboptimal cannot be settled at the present time.
3. The age of the thrombus is probably a crucial factor in determining the success of thrombolysis. Obviously, no fibrinolytic drug can dissolve a thrombus that has become organized (i.e., in which fibrin no longer is the predominanit component of the supporting framework) or which has been covered by endothelium. The time interval during which a clot remains susceptible to dissolution in a patient with thrombophlebitis is unknown. Studies on experimentally produced thrombi in the dog have indicated that success cannot be expected beyond the first 3 or 4 days.29' 38 Obviously, these results cannot be transferred directly to man. Experimentally formed clots in the dog may be handled quite differently in terms of organization and endothelialization than a spontaneously formed human clot.
Furthermore, venous occlusion in man may often be a progressive phenomenon. A venous thrombus may not be uniform in age and structure, and may contain some portions that are susceptible to lytic agents and others that are not.
Previously, definiite evidence of clinical response was noted in a minority of patients when fibrinolysin was administered more than 10 days after onset of phlebitic symptoms. 43 . 44 On the other hand, rapid clearing of phlebitis was almost uniformly encountered in those treated within 5 days of onset and in the majority treated between 5 and 10 days.
In view of these experiences, patienits with phlebitis of more than 10 days' duration were excluded Lrom the present study. In additioln, results in those patients treated within 5 The second objective, prevention of pulmonary embolization, seems to have been achieved although conlclusions in this regard must be dlrawn with caution. Three nionfatal and 1 " possible " fatal pulmonary embolus in the controls during the 2-week period after start of anticoagulanit therapy conitrast with the single " possible" nonfatal embolus in the fibrinolysin. group. Such a low incidenee in the latter patients is especially noteworthy wheni it is recalled that some 28 per cent of this group had suffered an elibolus preceding institutioin of therapy anid such patients are especially prone to develop further embolic episodes.'~The low incidence of embolizatioii in the group receiving combined therapy also indicates that the release of embolie material by fibrinolytic agents seemn unlikely.
Attainment of the third objective, preven tion of postphlebitic residual, was less clearly influenced by fibrinolvsin . The incidence oif this complication was quite low in both groups, however, especially in view of the high incidence of femoral and iliofemoral ocelusion which characterized the entire series.5," Definite conclusions regardinig the ability of fibrinolysin to reduce the iineidenee or extent of postphlebitic residuals must be deferred.
The data regarding early recurrenee are also rather difficult to interpret. While all 5 In terms of over-all mortality, the longterm results also are revealing. The 17 per cent mortality in the controls is a rather imposing figure in view of the limited period of follow-up, especially since embolization was at least a contributory factor in the death of 4 patients and probably the immediate cause of death in the fifth. In the fibrinolysin group, only 2 deaths are known to have occurredone due to carcinoma of the pancreas and the other due to uremia. While the inference may be drawn that fibrinolvsin therapy has reduced mortality due to early and late embolization, again more extensive data must be obtained before such conclusions are justified.
The analysis of the "early treatment" subgroups was carried out to test the hypothesis that the age of the thrombus will influence responise of the phlebitie subject to fibrinoCirculation, Volume XXI, March 1960 lysin. If this were so, differences between the fibrinolysin and control subgroups should be greater than those that exist between the two total groups. This expectation appears to be confirmed in regard to "short-term" results, especially in terms of response of the extremity itself. When analysis is limited to those treated promptly, the differenees in phlebitic course (table 7) between the coiitrol and treated groups become wider and more significant statistically. The absence of either early (within 2 weeks) embolization or recurrence in the fibrinolysin subgroup is also noteworthy, although the incidence of postphlebitic residuals is not appreciably lower than in the controls.
As in the "total groups," however, the apparent superiority of combined therapy is not so evident when long-term results are considered. While embolic incidence and mortality are lower in the fibrinolysin group, these data may be influenced by the follow-up period available in each group. Furthermore, the tendency toward recurrence does not appear to have been diminished in those receiving fibrinolysin. Finally, in assessing the over-all value of fibrinolysiii, we cannot negleet conisideration of its toxicity. The present stuidy has confirmed our previous impressions that the febrile response to this agent, while ulndesirable. does not impair its applicatioln in the great majority of patients with aeute th-ombophlebitis. However, antihistaminic prophylaxis is especially important in patienits with underlying disorders that might be unfavorably influenced by a short period of fever or chills (e.g., coronary artery disease). The possible risk of reaction in such individuals must be weighed against the expected benefits. Other theoretic dangers of fibrinolysin therapy, such as embolization or hemorrhage, have not proved of clinical importance. It should be recognized, however, that these statements regarding toxicity of the material apply only to the dosage regimen employed in these patients.
In addition to the information regarding the effect of fibrinolysin, the present study also supplies some data in an area that is relatively unexplored; namely, the long-term prognosis of phlebitic subjects. The majority of patients with thrombophlebitis recover completely after a relatively short period of bed rest and anticoagulant therapy. In the present series, the morbidity and mortality in both groups would have been extremely low if 
Summary
Sixty-two patients with deep thrombophlebitis of less than 10 days' duration were studied in controlled fashion. Thirty "c ontrol"' patients were treated by routine methods including anticoagulant drugs. Thirtytwo "treatment " patients received fibrinolysin (plasmin) in addition to conitrol therapy.
The composition of the groups studied and the protocol followed ar'e presented in detail.
Comparison of the 2 groups indicates that the addition of fibrinolysin to the therapeutic regimlen leads to more rapid clearing of the acute phlebitic episode and may diminish the short-termii incidence of phlebitic recurrence and pulmronary embolization. Postphlebitic residuals were encountered with almost equal frequeney in both groups.
Greater short-term differences in therapeutic response exist between control and fibrinolysin patients when analysis is restricted to Circulation, Volume XXI, March 1960 those treated within 
Summario in Interlingua
Sexanta-duo patientes con thrombophlebitis profunde de minus que 10 dies de duration esseva studiate sub conditiones a controlo. Trenta patientes, representante le gruppo de controlo, esseva tractate secundo le methodos routinari, incluse le uso de drogas anticoagulante. Trenta-duo patientes, representante le gruppo de tractamento, recipeva fibrinolysina (piasmina) a parte le therapia de coiitrolo.
Le composition del gruppos studiate e le technica experimental usate es presentate in detalio.
Le comparation del 2 gruppos indica que le addition de fibrinolysina al regime therapeutic resulta in un plus rapide resolution del episodio phlebitic acute e reduce possibilemente le incidentia a curte vista de recurrentias phlebitic e de embolisation pulmonar. Residuos postphlebitic esseva incontrate in le duo gruppos con quasi le mesme frequentia.
Plus notabile differentias immediate in le responsa therapeutic existe inter le patientes tractate con fibrinolysina e le patientes de controlo si le analyse es restringite a casos tractate intra 5 dies post le declaration del phlebitis.
Le datos currentemente disponibile non permitte firme conclusiones con respecto al apparentemente favorabile influentia de fibrinolysina super le prognose a longe vista pro le subjectos phlebitic, sed ille datos indica que recurrentias e embolisationes pote esser expectate in ambe gruppos.
Le factores que affice possibilemente le resultatos obtenite per le therapia fibrinolytic es discutite. Le importantia de prender los in consideration in studios de iste typo es sublineate.
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